Richter's transformation (RT) is an aggressive and incurable diffuse large B cell lymphoma (DLBCL) that clonally evolves from chronic lymphocytic leukemia (CLL), the most prevalent leukemia in adults. Patients who develop RT have few treatment options and face a grim prognosis of only 6-8 months despite aggressive multimodal therapy. Importantly, RT has become the most common type of disease progression observed in CLL patients receiving targeted therapies such as the BTK inhibitor Ibrutinib and the Bcl-2 inhibitor Venetoclax (ABT-199). As the use of these agents continues to grow, emergence of resistance and progression to RT are of increasing clinical concern. Recent data suggests that RT is a biologically and clinically distinct disease entity from CLL and DLBCL. Because of this, well-defined risk factors for CLL cannot be applied to predict which patients will develop RT, indicating clear, unmet needs to identify epigenomic lesions predictive of patients at the highest risk for transformation and to bring forward novel treatment options with real curative potential for this fatal complication. Clonal evolution is considered a key feature of cancer progression and relapse. About 80-90% of RT cases arise from the underlying CLL clone although the mechanisms driving RT are poorly understood. Currently no driver mutations have been identified leading to the hypothesis that acquired epigenetic lesions may favor the emergence of the more aggressive RT clone. Approximately 50% of RT tumors display epigenetic changes affecting cMYC over-expression and P53 inactivation, suggesting these pathways may play a major role in the pathogenesis of RT. BRD4 and PRMT5 are epigenetic modifiers essential for P53 and c-MYC activity that we have shown to have transforming potential in several lymphoma models. In contrast to CLL patients who do not develop RT, our preliminary data show that PRMT5 is abundantly over-expressed in CLL tumor cells months to years prior the development of RT. Novel targets of both PRMT5 and BRD4 regulation have not been characterized in CLL/RT. Our preliminary data supports the existence of a BRD4-PRMT5-MYC/P53 feed- forward loop that drives the malignant phenotype of RT and represents an ideal driver axis to deliver targeted therapy. This proposal will utilize a highly novel, integrated epigenomic approach to mechanistically address how BRD4 and PRMT5 contribute toward global epigenetic changes favoring the emergence of the RT clone. If successful our experiments will identify unique epigenomic disease associated with risk of RT. Additionally, the use of innovative, spontaneous, immune competent murine models of RT we have generated coupled with novel, first-in-class agents that selectively target BRD4 and PRMT5 place us in a unique position to make a significant impact for patients with this disease by developing preventive and therapeutic approaches that can be translated into the clinic.

Public Health Relevance

Richter's transformation (RT) is an aggressive, incurable blood cancer that arises when the most common leukemia, chronic lymphocytic leukemia, makes the transition to a high grade lymphoma. Our preliminary data and previously published work identifies BRD4 and PRMT5 proteins to be essential for the development of lymphoma, and that blocking the function of these proteins, using first in class drugs can effectively treat this cancer in laboratory and in pre-clinical animal models of RT. Here we propose to define the mechanisms by which BRD4 and PRMT5 contribute to development of RT with the goals of developing novel markers that can predict RT development as well as discover novel targeted therapeutic strategies for translation into clinical trials for patients with this incurable disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA214046-05
Application #
10084828
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Forry, Suzanne L
Project Start
2017-02-07
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
5
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Ozer, Hatice Gulcin; El-Gamal, Dalia; Powell, Ben et al. (2018) BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Cancer Discov 8:458-477
Smith, Emily; Zhou, Wei; Shindiapina, Polina et al. (2018) Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Expert Opin Ther Targets 22:527-545